Literature DB >> 15840468

Prevalence, mechanisms, and clinical significance of macroreentrant atrial tachycardia during and following left atrial ablation for atrial fibrillation.

Aman Chugh1, Hakan Oral, Kristina Lemola, Burr Hall, Peter Cheung, Eric Good, Kamala Tamirisa, Jihn Han, Frank Bogun, Frank Pelosi, Fred Morady.   

Abstract

OBJECTIVES: The purpose of this study was to determine the prevalence and clinical significance of macroreentrant atrial tachycardia (AT) after left atrial (LA) circumferential ablation for atrial fibrillation (AF).
BACKGROUND: Linear ablation for AF may result in macroreentrant AT.
METHODS: Three hundred forty-nine patients (age 54 +/- 11 years) underwent LA circumferential ablation for AF (paroxysmal in 227). Ablation lines were created around the left-sided and right-sided pulmonary veins, with additional ablation lines in the posterior LA and mitral isthmus. If macroreentrant AT was observed acutely in the electrophysiology laboratory, it was not ablated. If an organized AT occurred during follow-up, the initial strategy was rate control. If AT persisted for > 3 to 4 months, catheter ablation was performed.
RESULTS: Seventy-one patients (20%) had spontaneous or induced macroreentrant AT (cycle length 244 +/- 31 ms) in the electrophysiology laboratory following LA circumferential ablation. During follow-up, 85 patients (24%) experienced spontaneous AT (cycle length 238 +/- 35 ms) at a mean of 44 +/- 62 days following LA circumferential ablation. Among the 71 patients with macroreentrant AT acutely following LA circumferential ablation, 39 (55%) developed AT during follow-up. Among the 85 patients with AT during follow-up, the tachycardia remitted without a repeat ablation procedure in 28 patients (33%), most commonly within 5 months. Twenty-eight of the 349 patients (8%) underwent a repeat ablation procedure for AT. The critical isthmus was localized to the mitral isthmus in 17 of 28 patients (61%).
CONCLUSIONS: Macroreentrant AT is a common form of proarrhythmia after LA circumferential ablation for AF. Because it may resolve spontaneously, ablation of AT should be deferred for several months.

Entities:  

Mesh:

Year:  2005        PMID: 15840468     DOI: 10.1016/j.hrthm.2005.01.027

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  50 in total

1.  Ethanol infusion in the vein of Marshall facilitates mitral isthmus ablation.

Authors:  José L Báez-Escudero; Percy Francisco Morales; Amish S Dave; Christine M Sasaridis; Young-Hoon Kim; Kaoru Okishige; Miguel Valderrábano
Journal:  Heart Rhythm       Date:  2012-03-07       Impact factor: 6.343

2.  Atypical electrocardiographic features of cavotricuspid isthmus-dependent atrial flutter occurring during left atrial fibrillation ablation.

Authors:  Janice Y Chyou; Kathleen Hickey; Laurence Diamond; William Whang; Jose Dizon; Hasan Garan; Angelo Biviano
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-07       Impact factor: 1.468

3.  Curative catheter ablation for atrial fibrillation.

Authors:  Eric D Good; Hakan Oral
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-10

Review 4.  Antiarrhythmic therapy as an adjuvant to promote post pulmonary vein isolation success-a meta-analysis.

Authors:  Gustavo R Goldenberg; Daniel Burd; Piotr Lodzinski; Giuseppe Stabile; Jacob A Udell; David Newman; Mohammed Shurrab; Eugene Crystal
Journal:  J Interv Card Electrophysiol       Date:  2016-06-29       Impact factor: 1.900

5.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

6.  Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function.

Authors:  Ken Kato; Koichiro Ejima; Noritoshi Fukushima; Makoto Ishizawa; Osamu Wakisaka; Ryuta Henmi; Kentaro Yoshida; Toshiaki Nuki; Kotaro Arai; Bun Yashiro; Tetsuyuki Manaka; Kyomi Ashihara; Morio Shoda; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2015-01-30       Impact factor: 2.037

7.  Catheter ablation of atypical atrial flutter: a novel 3D anatomic mapping approach to quickly localize and terminate atypical atrial flutter.

Authors:  Sri Sundaram; William Choe; J Ryan Jordan; Nate Mullins; Charles Boorman; Eric J Kessler; Sunil Nath
Journal:  J Interv Card Electrophysiol       Date:  2017-06-29       Impact factor: 1.900

Review 8.  Ligament and vein of Marshall: A therapeutic opportunity in atrial fibrillation.

Authors:  Moisés Rodríguez-Mañero; Paul Schurmann; Miguel Valderrábano
Journal:  Heart Rhythm       Date:  2015-10-13       Impact factor: 6.343

Review 9.  Curing atrial fibrillation: Two decades of progress.

Authors:  N A Mark Estes; Ralph J Damiano
Journal:  J Interv Card Electrophysiol       Date:  2007-12       Impact factor: 1.900

10.  Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes.

Authors:  Naiara Calvo; Lluís Mont; David Tamborero; Antonio Berruezo; Graziana Viola; Eduard Guasch; Mercè Nadal; David Andreu; Barbara Vidal; Marta Sitges; Josep Brugada
Journal:  Europace       Date:  2010-01       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.